Valiant Laboratories Ltd
Fri 22/05/2026,15:40:46 | NSE : VALIANTLAB
Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.
Market Data
Essential tool: analyze, trade, manage, decide.
Open
₹ 75.97
Previous Close
₹ 75.97
Volume
6434
Mkt Cap ( Rs. Cr)
₹417.55
High
₹ 77.25
Low
₹ 75.00
52 Week High
₹ 114.52
52 Week Low
₹ 49.51
Book Value Per Share
₹ 57.13
Dividend Yield
0.00
Face Value
₹ 10.00
What’s Your Call?
Collective community sentiment on Valiant Laboratories Ltd
Your Vote -
Buy
66.67%
Hold
0.00%
Sell
33.33%
66.67%
3 users have voted
Market Depth
How many stocks are available to buy or sell and at what prices.
Buy Order Quantity
0%
Sell Order Quantity
100%
Bid Price
Qty
0.00
0
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
0
Bid Price
Qty
81.65
750
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
750
Option Chain
Analyzes market sentiment, predicts Valiant Laboratories Ltd' movement.
NO_RECORD_FOUND
News
Media spotlight triggers stock stock attention, sentiment.
-
Valiant Laboratories - Disclosure under SEBI Takeover Regulations
-
Valiant Laboratories - Updates
-
Valiant Laboratories - Intimation Recieved Under Regulation 10(5) Of SEBI (SAST) Regulations, 2011
-
Valiant Laboratories - Announcement under Regulation 30 (LODR)-Press Release / Media Release
-
Valiant Laboratories - Press Release
-
Valiant Laboratories - Copy of Newspaper Publication
-
Valiant Laboratories Q4 net profit up 8.95% at Rs 3.53 cr
-
Valiant Laboratories - Announcement under Regulation 30 (LODR)-Monitoring Agency Report
-
Valiant Laboratories - Monitoring Agency Report
-
Valiant Laboratories - Audited Standalone And Consolidated Financial Results For Quarter And Year Ended March 31, 2026.
-
Valiant Laboratories - Outcome of Board Meeting
-
Valiant Laboratories - Appointment Of Cost Auditor And Internal Auditor
-
Valiant Laboratories - Outcome of Board Meeting
-
Valiant Laboratories - Audited Standalone And Consolidated Financial Results For Quarter And Year Ended March 31, 2026.
-
Valiant Laboratories - Board Meeting Outcome for Audited Standalone And Consolidated Financial Results For Quarter And Year E
-
Valiant Laboratories - Outcome of Board Meeting
-
Valiant Laboratories - Board Meeting Intimation for Approval Of Financial Results For Quarter And Year Ended March 31, 2026
-
Valiant Laboratories - Resignation of Director/KMP/SMP
-
Valiant Laboratories - Resignation
-
Valiant Laboratories - Announcement under Regulation 30 (LODR)-Change in Management
-
Valiant Laboratories has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2026
-
Valiant Laboratories - Certificate under SEBI (Depositories and Participants) Regulations, 2018
-
Valiant Laboratories - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
-
Valiant Laboratories - Trading Window
Key fundamentals
Evaluate the intrinsic value of Valiant Laboratories Ltd stock
| Name | March-26 | March-25 | March-24 | March-23 | March-22 |
|---|---|---|---|---|---|
| Assets | 319.7587 | 293.7833 | 296.2821 | 159.89 | 132.141 |
| Liabilities | 319.7587 | 293.7833 | 296.2821 | 159.89 | 132.141 |
| Equity | 54.3125 | 43.45 | 43.45 | 32.56 | 16.28 |
| Gross Profit | 7.1761 | -4.676 | -8.4083 | 35.09 | 42.318 |
| Net Profit | 5.5482 | -2.1502 | 0.3403 | 28.998 | 27.496 |
| Cash From Operating Activities | -13.8064 | -21.9012 | 48.7819 | 22.956 | 2.251 |
| NPM(%) | 2.55 | -1.61 | 0.18 | 8.68 | 9.43 |
| Revenue | 217.0425 | 133.3618 | 182.0525 | 333.91 | 291.523 |
| Expenses | 209.8664 | 138.0378 | 190.4608 | 298.82 | 249.205 |
| ROE(%) | 1.78 | -0.69 | 0.1 | 9.34 | 8.86 |
Corporate Action
| XD-Date | Dividend-Amount | Dividend-% | Dividend Yield(%GE) | Price on that day |
|---|
Peers
Other companies within the same industry or sector that are comparable to Valiant Laboratories Ltd
| Company | Price | Price (% change) | pe(x) | EV/EBITDA(x) | ROE(%) | ROCE(%) |
|---|---|---|---|---|---|---|
| Albert David Ltd | 705.80 | -0.07 | 0.00 | 44.62 | -26.19 | 0.71 |
| Lotus Eye Hospital and Institute Ltd | 109.19 | 1.26 | 352.23 | 162.61 | 3.55 | 0.00 |
| Vaishali Pharma Ltd | 7.00 | 0.14 | 0.00 | 1020.08 | 3.13 | 0.00 |
| Astec Lifesciences Ltd | 771.80 | 4.77 | 0.00 | 153.34 | -363.15 | 0.00 |
Company Info
The Company was originally formed as a partnership firm under Indian Partnership Act, 1932, under the name and style of "M/s Bharat Chemicals" pursuant to the deed of partnership dated October 17, 1980. Subsequently, the partnership firm, M/s. Bharat Chemicals was converted into a public limited company under the provisions of the Companies Act with the name "Valiant Laboratories Limited" pursuant to certificate of incorporation dated August 16, 2021 issued by Central Registration Centre, Registrar of Companies. The corporate identity number of the Company is U24299MH2021PLC365904.Key events and milestones :1980- Formed M/s. Bharat Chemicals (a partnership firm)1981- Acquired plot No. L-30 in the Tarapur Industrial Area, Palghar, Maharashtra on leasehold basis admeasuring about 1,000 sq. mtrs1982- Commenced manufacture of Paracetamol2004-05- Acquired additional Plot Nos. L-28, L-28 (part), L-29 and L-13 at Tarapur Industrial Area, Palghar, Maharashtra collectively admeasuring about 3,000 sq.mtrs2015- The annual revenue from operations crossed Rs.500 million2021- Converted from partnership firm into a public limited company- The annual revenue from operations crossed Rs.1,000 million2022- The annual revenue from operations crossed Rs.2,000 million- Formed the wholly owned subsidiary, VASPL to diversify the business activities 2025 -The company issued rights shares of Rs. 10 in the ratio of 1:4 at a premium of Rs. 65 per share.
The Company was originally formed as a partnership firm under Indian Partnership Act, 1932, under the name and style of "M/s Bharat Chemicals" pursuant to the deed of partnership dated October 17, 1980. Subsequently, the partnership firm, M/s. Bharat Chemicals was converted into a public limited company under the provisions of the Companies Act with the name "Valiant Laboratories Limited" pursuant to certificate of incorporation dated August 16, 2021 issued by Central Registration Centre, Registrar of Companies. The corporate identity number of the Company is U24299MH2021PLC365904.Key events and milestones :1980- Formed M/s. Bharat Chemicals (a partnership firm)1981- Acquired plot No. L-30 in the Tarapur Industrial Area, Palghar, Maharashtra on leasehold basis admeasuring about 1,000 sq. mtrs1982- Commenced manufacture of Paracetamol2004-05- Acquired additional Plot Nos. L-28, L-28 (part), L-29 and L-13 at Tarapur Industrial Area, Palghar, Maharashtra collectively admeasuring about 3,000 sq.mtrs2015- The annual revenue from operations crossed Rs.500 million2021- Converted from partnership firm into a public limited company- The annual revenue from operations crossed Rs.1,000 million2022- The annual revenue from operations crossed Rs.2,000 million- Formed the wholly owned subsidiary, VASPL to diversify the business activities 2025 -The company issued rights shares of Rs. 10 in the ratio of 1:4 at a premium of Rs. 65 per share.
Read More
Parent Organisation
Valiant Laboratories Ltd.
Founded
06/08/2021
Managing Director
Mr.Santosh S Vora
NSE Symbol
VALIANTLABBE
FAQ
The current price of Valiant Laboratories Ltd is ₹ 76.88.
The 52-week high for Valiant Laboratories Ltd is ₹ 77.25 and the 52-week low is ₹ 75.00.
The market capitalization of Valiant Laboratories Ltd is currently ₹ 417.55. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.
To buy Valiant Laboratories Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.
To invest in Valiant Laboratories Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Valiant Laboratories Ltd shares.
The CEO of Valiant Laboratories Ltd is Mr.Santosh S Vora, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.
